Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem

Antibody-mediated blockade of co-inhibitory molecules such as cytotoxic T lymphocyte-associated protein 4, PD1 and PDL1 elicits potent antitumor responses and improves the prognosis of many patients with cancer. As these immune checkpoint inhibitors (ICIs) are increasingly prescribed to a diverse pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Poels, Kikkie, Neppelenbroek, Suzanne I.M., Kersten, Marie José, Antoni, M. Louisa, Lutgens, Esther, Seijkens, Tom T.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231062/
https://www.ncbi.nlm.nih.gov/pubmed/34168005
http://dx.doi.org/10.1136/jitc-2021-002916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231062/
https://www.ncbi.nlm.nih.gov/pubmed/34168005
http://dx.doi.org/10.1136/jitc-2021-002916

Ejemplares similares